Should Off-Label Drugs Be Included as Comparators in Pharmacoeconomic Studies?

PharmacoEconomics

Volumn 32, Issue 11, 2014, Pages 1035-1037

  Walton, Surrey M ^a   Schumock, Glen T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; NEUROLEPTIC AGENT;

AGE RELATED MACULAR DEGENERATION; ANEMIA; CHECKLIST; CLINICAL DECISION MAKING; CONGESTIVE HEART FAILURE; COST CONTROL; ECONOMIC EVALUATION; EDITORIAL; ELECTRONIC MEDICAL RECORD; EUROPE; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEART FAILURE; HUMAN; ICD-10; ICD-9; MEDICAID; MEDICARE; OFF LABEL DRUG USE; OUTCOMES RESEARCH; PATENT; PEER REVIEW; PHARMACOECONOMICS; PHYSICIAN; PRACTICE GUIDELINE; UNITED STATES; COST; ECONOMICS; PROCEDURES;

COSTS AND COST ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; OFF-LABEL USE;

EID: 84910123845     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0222-2     Document Type: Editorial

References (16)

1. Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy. 2008;28:1443–52.
2. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021–6.
3. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf. 2011;20:177–84.
4. Kitamura M. Italy to fund unapproved use of roche drug to cut costs. In: Bloomberg News. 2014. http://www.bloomberg.com/news/2014-06-10/italy-to-fund-unapproved-use-of-roche-drug-to-cut-costs.html. Accessed 13 Aug 2014.
5. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14:417–28.
6. Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14:429–37.
7. Palazzuoli A, Ruocco G, Pellegrini M, et al. The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. Ther Clin Risk Manag. 2014;10:641–50.
8. KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47:S11–145.
9. Falck S, Adimadhyam S, Meltzer DO, Walton SM, Galanter WL. A trial of indication based prescribing of antihypertensive medications during computerized order entry to improve problem list documentation. Int J Med Inform. 2013;82:996–1003.
10. Walton SM, Galanter WL, Rosencranz H, et al. A trial of inpatient indication based prescribing during computerized order entry with medications commonly used off-label. Appl Clin Inform. 2011;2:94–103.
11. Jackson J. FDAMA 1997 section 114: another look. Value Health. 2009;12:191–2.
12. Neumann PJ. What ever happened to FDAMA section 114? A look back after 10 years. Value Health. 2009;12:189–90.
13. Dennis B. FDA has free-speech, safety issues to weigh in review of ‘off-label’ drug marketing rules. In: The Washington Post. 2014. http://www.washingtonpost.com/national/health-science/2014/07/09/3708dd6a-fbc4-11e3-8176-f2c941cf35f1_story.html. Accessed 13 Aug 2014.
14. Afzali HH, Karnon J, Merlin T. Improving the accuracy and comparability of model-based economic evaluations of health technologies for reimbursement decisions: a methodological framework for the development of reference models. Med Decis Making. 2013;33:325–32.
15. Paczynski RP, Alexander GC, Chinchilli VM, Kruszewski SP. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications. Int J Risk Saf Med. 2012;24:137–46.
16. Abernethy AP, Raman G, Balk EM, et al. Systematic review: reliability of compendia methods for off-label oncology indications. Ann Intern Med. 2009;150:336–43.